The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Dysplastic Nevus Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dysplastic Nevus Syndrome


High impact information on Dysplastic Nevus Syndrome


Chemical compound and disease context of Dysplastic Nevus Syndrome


Biological context of Dysplastic Nevus Syndrome


Anatomical context of Dysplastic Nevus Syndrome


Gene context of Dysplastic Nevus Syndrome


Analytical, diagnostic and therapeutic context of Dysplastic Nevus Syndrome

  • Immunohistochemistry on paraffin-embedded tissue sections of 159 cases revealed a significant increase in intensity of ETB receptor expression from common nevi over dysplastic nevi and primary MM to metastatic MM [30].


  1. Hereditary dysplastic nevus syndrome: lymphoid cell ultraviolet hypermutability in association with increased melanoma susceptibility. Perera, M.I., Um, K.I., Greene, M.H., Waters, H.L., Bredberg, A., Kraemer, K.H. Cancer Res. (1986) [Pubmed]
  2. Versican is differentially expressed in human melanoma and may play a role in tumor development. Touab, M., Villena, J., Barranco, C., Arumí-Uría, M., Bassols, A. Am. J. Pathol. (2002) [Pubmed]
  3. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Park, W.S., Vortmeyer, A.O., Pack, S., Duray, P.H., Böni, R., Guerami, A.A., Emmert-Buck, M.R., Liotta, L.A., Zhuang, Z. Hum. Pathol. (1998) [Pubmed]
  4. Silver staining of nucleolar organizer regions in malignant melanoma and melanotic nevi. Leong, A.S., Gilham, P. Hum. Pathol. (1989) [Pubmed]
  5. UVB-induced decrease of p16/CDKN2A expression in skin cancer patients. Krähn, G., Leiter, U., Udart, M., Kaskel, P., Peter, R.U. Pigment Cell Res. (2001) [Pubmed]
  6. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., Prins, D.E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., Frants, R.R. Nat. Genet. (1995) [Pubmed]
  7. DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. Landi, M.T., Baccarelli, A., Tarone, R.E., Pesatori, A., Tucker, M.A., Hedayati, M., Grossman, L. J. Natl. Cancer Inst. (2002) [Pubmed]
  8. Detection of p53 mutations in benign and dysplastic nevi. Levin, D.B., Wilson, K., Valadares de Amorim, G., Webber, J., Kenny, P., Kusser, W. Cancer Res. (1995) [Pubmed]
  9. Effects of topical tretinoin on dysplastic nevi. Halpern, A.C., Schuchter, L.M., Elder, D.E., Guerry, D., Elenitsas, R., Trock, B., Matozzo, I. J. Clin. Oncol. (1994) [Pubmed]
  10. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. Guerry, D., Alexander, M.A., Elder, D.E., Herlyn, M.F. J. Immunol. (1987) [Pubmed]
  11. Image analysis cytometry of dysplastic nevi. Fleming, M.G., Wied, G.L., Dytch, H.E. J. Invest. Dermatol. (1990) [Pubmed]
  12. Diet and melanoma in a case-control study. Millen, A.E., Tucker, M.A., Hartge, P., Halpern, A., Elder, D.E., Guerry, D., Holly, E.A., Sagebiel, R.W., Potischman, N. Cancer Epidemiol. Biomarkers Prev. (2004) [Pubmed]
  13. Effect of oral isotretinoin on dysplastic nevi. Edwards, L., Meyskens, F., Levine, N. J. Am. Acad. Dermatol. (1989) [Pubmed]
  14. Estrogen and progesterone receptors in melanocytic lesions. Occurrence in patients with dysplastic nevus syndrome. Ellis, D.L., Wheeland, R.G., Solomon, H. Archives of dermatology. (1985) [Pubmed]
  15. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. van der Velden, P.A., Sandkuijl, L.A., Bergman, W., Pavel, S., van Mourik, L., Frants, R.R., Gruis, N.A. Am. J. Hum. Genet. (2001) [Pubmed]
  16. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Chaudru, V., Laud, K., Avril, M.F., Minière, A., Chompret, A., Bressac-de Paillerets, B., Demenais, F. Cancer Epidemiol. Biomarkers Prev. (2005) [Pubmed]
  17. Hereditary malignant melanoma: a unifying etiologic hypothesis. Lynch, H.T., Fusaro, R.M. Cancer Genet. Cytogenet. (1986) [Pubmed]
  18. The T1796A mutation of the BRAF gene is absent in Spitz nevi. Palmedo, G., Hantschke, M., Rütten, A., Mentzel, T., Hügel, H., Flaig, M.J., Yazdi, A.S., Sander, C.A., Kutzner, H. J. Cutan. Pathol. (2004) [Pubmed]
  19. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Li, L.X., Crotty, K.A., McCarthy, S.W., Palmer, A.A., Kril, J.J. The American Journal of dermatopathology. (2000) [Pubmed]
  20. Comet assay demonstrates a higher ultraviolet B sensitivity to DNA damage in dysplastic nevus cells than in common melanocytic nevus cells and foreskin melanocytes. Noz, K.C., Bauwens, M., van Buul, P.P., Vrolijk, H., Schothorst, A.A., Pavel, S., Tanke, H.J., Vermeer, B.J. J. Invest. Dermatol. (1996) [Pubmed]
  21. Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study. Palazzo, J., Duray, P.H. Hum. Pathol. (1989) [Pubmed]
  22. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Goldstein, A.M., Landi, M.T., Tsang, S., Fraser, M.C., Munroe, D.J., Tucker, M.A. Cancer Epidemiol. Biomarkers Prev. (2005) [Pubmed]
  23. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Rulyak, S.J., Brentnall, T.A., Lynch, H.T., Austin, M.A. Cancer (2003) [Pubmed]
  24. Giant melanosomes in the dysplastic nevus syndrome. Electron microscopic observations. Hull, M.T., Epinette, W.W. Dermatologica (1984) [Pubmed]
  25. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Sun, S., Pollock, P.M., Liu, L., Karimi, S., Jothy, S., Milner, B.J., Renwick, A., Lassam, N.J., Hayward, N.K., Hogg, D., Narod, S.A., Foulkes, W.D. Int. J. Cancer (1997) [Pubmed]
  26. The genetics of hereditary melanoma and nevi. 1998 update. Greene, M.H. Cancer (1999) [Pubmed]
  27. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions. Wang, H., Shen, S.S., Wang, H., Diwan, A.H., Zhang, W., Fuller, G.N., Prieto, V.G. J. Cutan. Pathol. (2003) [Pubmed]
  28. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. Eskandarpour, M., Hashemi, J., Kanter, L., Ringborg, U., Platz, A., Hansson, J. J. Natl. Cancer Inst. (2003) [Pubmed]
  29. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. Ledda, F., Bravo, A.I., Adris, S., Bover, L., Mordoh, J., Podhajcer, O.L. J. Invest. Dermatol. (1997) [Pubmed]
  30. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Demunter, A., De Wolf-Peeters, C., Degreef, H., Stas, M., van den Oord, J.J. Virchows Arch. (2001) [Pubmed]
WikiGenes - Universities